MDACC Study No:2012-0308 ( NCT No: NCT01621490)
Title:An Exploratory Study of the Biologic Effects of BMS-936558 (Anti-PD-1 Monoclonal Antibody) Treatment in Subjects with Advanced Melanoma (Unresectable or Metastatic)
Principal Investigator:Wen-Jen Hwu
Treatment Agent:BMS-936558
Study Status:Closed
Study Description:The goal of this clinical research study is to learn about the effects of
nivolumab BMS-936558 on patients with advanced melanoma. The safety of this
drug will also be studied.

BMS-936558 is designed to help the immune system fight tumor cells.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:N/A
Treatment Agents:BMS-936558
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Bristol-Myers Squibb
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Wen-Jen Hwu
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults